The “159 pill” refers to a specific formulation of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Cipla Ltd. as a round, pale yellow tablet imprinted with “CIPLA” on one side and “159” on the other, containing 15 mg of the active ingredient.
Identification and Appearance
This pill is easily identifiable by its distinctive markings and color. It measures about 8 mm in diameter, with a flat, beveled edge, and may appear white in some lighting despite its official pale yellow hue.
Produced by Cipla USA, it falls under NDC code 69097-159 and is available by prescription only. Consumers often search for it using terms like “159 white round pill” or “Cipla 159,” distinguishing it from similar lower-dose variants like the Cipla 158 (7.5 mg).
Active Ingredient and Mechanism
Meloxicam selectively inhibits the COX-2 enzyme over COX-1, reducing prostaglandin production that causes pain, swelling, and fever.
This COX-2 preference offers a better gastrointestinal safety profile than older NSAIDs like ibuprofen, though risks remain. Peak blood levels occur 5-6 hours post-dose, with a 15-20 hour half-life enabling once-daily use; it’s metabolized in the liver and excreted via urine.
Approved Medical Uses
Primarily indicated for osteoarthritis (OA), where it alleviates joint pain and stiffness to improve mobility. For rheumatoid arthritis (RA), it manages chronic inflammation, often alongside disease-modifying drugs like methotrexate.
In juvenile RA (for patients ≥60 kg), it controls fever and tenderness. Off-label, it’s used for gout flares, ankylosing spondylitis back pain, and occasionally post-surgical discomfort, though not first-line for CABG-related pain.
Dosage Guidelines
Adults typically take one 15 mg tablet once daily with food and water to minimize stomach upset; do not exceed 15 mg/24 hours.
For acute pain, loading doses up to every 12 hours on day one may apply under supervision. Dose adjustments are needed for kidney/liver impairment; it’s not recommended in late pregnancy or for children under 2 years.
Common Side Effects
Gastrointestinal issues like heartburn, nausea, or ulcers are frequent; cardiovascular risks include elevated blood pressure or heart events with long-term use.
Other effects encompass rash, dizziness, headache, and rare but serious kidney/liver damage. Monitor for bleeding risks, especially with alcohol or anticoagulants.
Serious Risks and Contraindications
Black-box warnings highlight heart attack/stroke and GI bleeding risks, particularly in high-risk patients.
Avoid in active peptic ulcers, severe heart failure, or post-CABG surgery. Drug interactions occur with SSRIs, lithium, methotrexate, and other NSAIDs; alcohol amplifies GI hazards. Allergic reactions (anaphylaxis) can mimic aspirin sensitivity.
Precautions and Monitoring
Take with food; stay hydrated to protect kidneys. Regular blood tests track liver/kidney function and blood counts.
Not for self-medication—consult physicians for long-term use, especially with hypertension, asthma, or bleeding disorders. Discontinue if edema, unexplained weight gain, or skin issues arise.
| Feature | Meloxicam (159 Pill) | Ibuprofen | Naproxen |
|---|---|---|---|
| COX Selectivity | COX-2 preferential | Non-selective | Non-selective |
| Dosing Frequency | Once daily | 3-4 times daily | Twice daily |
| GI Risk Profile | Lower than others | Higher | Moderate |
| Half-Life | 15-20 hours | 2-4 hours | 12-17 hours |